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AbstrAct
CD5 is a pan-T-cell surface marker and is rarely expressed in diffuse large 
B-cell lymphoma (DLBCL). Large-scale studies of de novo CD5+ DLBCL are lacking 
in Western countries. In this study by the DLBCL Rituximab-CHOP Consortium, 
CD5 was expressed in 5.5% of 879 DLBCL patients from Western countries. CD5+ 
DLBCL was associated with higher frequencies of >1 ECOG performance status, bone 
marrow involvement, central nervous system relapse, activated B-cell–like subtype, 
Bcl-2 overexpression, and STAT3 and NF-κB activation, whereas rarely expressed 
single-stranded DNA-binding protein 2 (SSBP2), CD30 or had MYC mutations. With 
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IntroductIon
CD5 is a cell surface glycoprotein typically 
expressed on normal and neoplastic T- cells, as well as on a 
subset of normal naïve B-cells and lymphoma cells, mainly 
in chronic lymphocytic leukemia/small lymphocytic 
lymphoma (CLL/SLL) and mantle cell lymphoma [1-4]. 
CD5 has an immunoreceptor tyrosine inhibitory motif and 
functionally inhibits the T-cell response [5,6] and B-cell 
receptor (BCR) signaling-mediated apoptosis, probably 
by recruiting the SH2 domain-containing protein tyrosine 
phosphatase-1 (SHP-1) after being phosphorylated by 
Lyn [7,8]. In lymphocytes, CD5 also inhibits signaling 
downstream of the BCR pathway, including the calcium 
response and interleukin-2 (IL2) production whereas 
augments BCR-mediated IL10 production, an anti-
inflammatory cytokine and a survival factor for B-cells 
[9,10]. In CLL/SLL, CD5 governs the phosphorylation 
and nuclear translocation of STAT3 and nuclear factor of 
activated T cells 2 (NFAT2); activated STAT3/NFAT2 in 
turn leads to excess production of IL10 [11,12]. 
CD5 has also been found to be expressed, albeit 
rarely, in de novo diffuse large B-cell lymphoma (DLBCL). 
To date, large-scale studies of de novo CD5+ DLBCL have 
been conducted only in Japan, with a reported frequency 
of 5 to 22% of all DLBCL [13-20]. Compared with 
patients with CD5– DLBCL, CD5+ DLBCL patients are 
reportedly more often elderly, female, and have >1 ECOG 
performance status, elevated serum lactate dehydrogenase 
(LDH) level, advanced stage disease, >1 extranodal 
sites, B-symptoms, and high International Prognostic 
Index (IPI) at diagnosis [13,14,19]. Pathologically, CD5+ 
DLBCL are associated with centroblastic morphology 
(rarely immunoblastic), Bcl-2 overexpression, and non-
germinal center B-cell (non-GCB) subtype [16,19]. 
Most studies from Japan have shown that clinical 
outcomes of CD5+ DLBCL patients treated with 
standard CHOP (cyclophosphamide, doxorubicin, 
vincristine, and prednisone) chemotherapy with or 
without rituximab are poor, although the prognostic 
significance of CD5 positivity may depend on associated 
aggressive clinical parameters [13-15,17,19]. Bone 
marrow (BM) involvement (28%) and central nervous 
system (CNS) relapse (12.7%) are increased in CD5+ 
DLBCL patients [14,16,20]. However, in one study 
CD5 expression status did not correlate with prognosis 
by univariate or multivariate analysis, either in all 
patients or in rituximab-treated patients [18]. The effect 
of adding rituximab to CHOP on survival of CD5+ 
DLBCL patients also has been inconsistent in different 
studies [18-20]. In Western countries, a few cases of de 
novo CD5+ DLBCL have been reported [21,22], and a 
morphologic and immunophenotypic study of 13 cases 
of de novo CD5+ DLBCL showed heterogeneous features 
[23]. No large-scale study of CD5+ DLBCL in Western 
countries has been performed with attention focused on 
the clinicopathological features and clinical response to 
R-CHOP. 
Biological study of CD5+ DLBCL can enhance 
understanding of the pathogenesis. Recent gene 
expression profiling (GEP) analysis by two groups 
yielded contradictory results. In one study comparison 
of 11 de novo CD5+ DLBCL and 9 CD5– DLBCL 
cases showed upregulation of integrin-β 1 and/or 
CD36 adhesion molecules, which were confirmed by 
immunohistochemistry (IHC) to be expressed in tumor 
cells and vascular endothelia, respectively [24]. In another 
study that compared 22 CD5+ and 26 CD5– DLBCL cases, 
CD5 positivity was associated with downregulation of 
extracellular matrix (ECM)-related genes [25]. 
The purpose of this study is to assess the frequency, 
clinicopathologic and biological features of de novo CD5+ 
DLBCL and to evaluate the prognostic significance of 
CD5 expression in DLBCL treated with rituximab-CHOP 
(R-CHOP) in Western countries. 
results
Frequency of cd5 expression in dlbcl and 
associated clinicopathologic features 
Figures 1A-B shows representative positive and 
negative CD5 IHC staining in DLBCL. We observed that 
thirty (5.6%) DLBCLs in the training set, and eighteen 
(5.3%) DLBCLs in the validation set were CD5 positive 
DLBCL. Expression of CD5 was noted on most tumor 
standard R-CHOP chemotherapy, CD5+ DLBCL patients had significantly worse 
overall survival (median, 25.3 months vs. not reached, P< .0001) and progression-
free survival (median, 21.3 vs. 85.8 months, P< .0001) than CD5– DLBCL patients, 
which was independent of Bcl-2, STAT3, NF-κB and the International Prognostic 
Index. Interestingly, SSBP2 expression abolished the prognostic significance of CD5 
expression, suggesting a tumor-suppressor role of SSBP2 for CD5 signaling. Gene-
expression profiling demonstrated that B-cell receptor signaling dysfunction and 
microenvironment alterations are the important mechanisms underlying the clinical 
impact of CD5 expression. This study shows the distinctive clinical and biological 
features of CD5+ DLBCL patients in Western countries and underscores important 
pathways with therapeutic implications.
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cells of CD5+ DLBCL; 67% of CD5+ tumors had >80% 
of the tumor cells positive for CD5. Most (76.7%) 
CD5+ DLBCL patients were of activated B-cell–like 
(ABC) subtype (Figure 1C). CD5+ patients DLBCL had 
significantly higher CD5 mRNA levels compared to CD5– 
DLBCL patients (P = .0019, Supplemental Figures 1A-B).
Comparison of the clinical characteristics of CD5+ 
vs. CD5– DLBCL patients in the training set showed that 
CD5+ DLBCL patients were more frequently elderly (>60 
years), and had B-symptoms, high performance status, an 
IPI score >2, and BM involvement (Table 1). None of the 
CD5+ patients, compared to eight (1.6%) CD5– DLBCL 
patients, showed CNS involvement at diagnosis. However, 
four (8.3%) CD5+ DLBCL patients had CNS relapse 
during follow-ups. 
Pathological features of CD5+ vs. CD5– DLBCL 
patients were characterized by comparing their protein 
expression profiles (Table 2 showed the results for most 
but not all the biomarkers in 879 patients). CD5+ DLBCL, 
as compared with CD5– DLBCL, were more often positive 
for Bcl-2, FOXP1, pSTAT3, c-Rel and CXCR4, and less 
often expressed GCET, CD10, CD30, and SSBP2 (single-
stranded DNA binding protein 2), or had MYC nonsilent 
mutations (Table 2, Supplemental Figures 1C-E). REL 
amplification or BCL2 translocation, which was found in 
only one CD5+ GCB-DLBCL DLBCL, did not account 
for the increased c-Rel or Bcl-2 level. CD5+ DLBCL also 
had no association with BCL2 amplifications, unlike one 
earlier study [26]. When comparison was restricted to 
the ABC subtype, CD5+ DLBCL were associated with 
significantly higher frequencies of Bcl-2+ and pSTAT3+ 
and lower frequencies of MYC mutations, CD30+, SSBP2+, 
and NF-κB1/p50+ (Table 2). 
Figure 1: Expression and prognostic significance of CD5 in de novo dlbcl. (A-B) Representative of CD5+ and CD5– 
immunohistochemical staining; (C) Distribution and comparison of CD5 expression between GCB- and ABC-DLBCL; (D-I) CD5 
expression was correlated with significantly poor OS and PFS in the overall, GCB-, and ABC- DLBCL cohorts; (J-K) Bone marrow 
involvement was correlated with significantly poorer OS and PFS in patients with CD5+ DLBCL; (L) Expression of CXCR4 in CD5+ and 
CD5– GCB- or ABC-DLBCL patients. 
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Note: LDH, serum lactate dehydrogenase; IPI, International Prognostic Index; BM, bone marrow; COO, cell-or-origin; GCB, 
germinal center B-like; ABC, activated B-cell like.
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CD5 expression is associated with significantly 
poorer survival in dlbcl
CD5+ DLBCL patients had significantly poorer 
overall survival (OS) (median OS: 25.3 months vs. not 
reached, hazard ratio [HR]: 3.87, 95% confidence interval 
[CI] of rate: 1.99-7.51, P < .0001) and progression-free 
survival (PFS) (median PFS: 21.3 vs. 85.8 months, HR: 
4.31, 95% CI: 2.26-8.23, P < .0001) in the training set, 
regardless of cell-of-origin (COO) (Figures 1D-I). The 
5-year OS rates for patients with CD5+ vs. CD5– DLBCL 
were 35.5% vs. 64.8%, and the 5-year PFS rates for 
patients with CD5+ vs. CD5– DLBCL were 29.6% vs. 59%, 
respectively. Between CD5+ patients with GCB- and ABC-
DLBCL there was no significant difference in OS or PFS 
(P = .76 for OS, and P = .51 for PFS). 
BM involvement significantly impacted OS (P 
= .0052) and PFS (P = .033) of CD5+ DLBCL patients 
(Figures 1J-K), and CD5 expression appeared to 
impact nodal DLBCL more than extranodal DLBCL 
(Supplemental Figures 1F-I) in the training set. CXCR4, 
a chemokine receptor involved in tumor cell homing to 
bone marrow and lymph node [27-29] was expressed 
at higher levels in CD5+ compared with CD5– DLBCL 
(P= .05, Supplemental Figure 1E). However, only in 
GCB-DLBCL was expression of CXCR4 significantly 
upregulated (P = .044). Expression levels of CXCR4 in 
CD5+ were similar to that in CD5–ABC-DLBCL (P = .59), 
although significantly higher than in CD5– patients with 
GCB-DLBCL (P = .028, Figure 1L). 
effect on bcl-2 expression and prognostic 
independence of cd5 expression
Almost 75% of CD5+ DLBCL patients had 
concurrent overexpression (≥70% of the tumor cells) of 
antiapoptotic Bcl-2, an unfavorable biomarker [30,31]. 
This frequency was significantly higher than that in CD5– 
DLBCL patients (53%, P = .0039, Table 2). Moreover, 
the correlation of CD5+ and Bcl-2 overexpression was 
observed at both the mRNA and protein levels and 
remained significant in the comparison of CD5+ with 
CD5– DLBCL within the ABC subtype, which commonly 
overexpressed Bcl-2 (Figures 2A-D). 
However, CD5 expression predicted unfavorable 
clinical outcomes independent of Bcl-2+ status in the 
overall or ABC-DLBCL (Figures 2E-L), and vice versa.
Figure 2: Correlation between CD5 and Bcl-2 overexpression and the prognostic significance of CD5 expression in 
dlbcl independent of bcl-2 overexpression. (A-D) CD5 expression was correlated with Bcl-2 overexpression and upregulated 
mRNA levels, in both GCB and ABC subtypes; (E-H) The prognostic significance of CD5+ was independent of Bcl-2 overexpression in 
DLBCL; (I-L) The prognostic significance of CD5+ was independent of Bcl-2 overexpression in ABC-DLBCL.
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Effect on NF-κB and STAT3 activation and 
prognostic independence of cd5 expression 
CD5 expression was associated with nuclear 
expression of the NF-κB subunits c-Rel and p65, but not 
mRNA levels of REL or RELA (Figures 3A-D, Table 2, 
Supplemental Figures 1J-K). However, nuclear expression 
of p50, which is also indicative of canonical NF-κB 
pathway activation [32], was significantly decreased in 
CD5+ ABC-DLBCL (Figure 3E, Table 2), which was not 
due to the NFKB1 downregulation at the mRNA level 
(Supplemental Figure 1L). There was no correlation 
between CD5+ and nuclear expression of p52 or RelB, 
two subunits involved in noncanonical/alternative NF-
κB pathway activation [32] (although showing trends of 
downregulation in CD5+ DLBCL, Figures 3F-G). 
CD5+ was also associated significantly with nuclear 
expression of phosphorylated/activated STAT3 but not 
upreglulated STAT3 mRNA in the ABC-DLBCL subtype 
(Figure 3H, Supplemental Figure 1O). The nuclear 
expression of pSTAT3 has been associated with poorer 
survival [33].
However, the adverse effect of CD5 expression 
on prognosis did not depend on c-Rel, p65 or STAT3 
activation. In both c-Rel– and c-Rel+, p65– and p65+, 
and pSTAT3– and pSTAT3+ patients, CD5 expression 
correlated with significantly poorer OS and PFS (Figures 
3I-P, showing analysis in the combined training and 
validation sets due to the limited CD5+ cases). 
Frequent loss of ssbP2 expression in cd5+ 
dlbcl
CD5 positivity in DLBCL was frequently associated 
with lack of SSBP2 expression, a tumor suppressor protein 
for lymphoma and leukemia (Figures 4A-D, Table 2) [34-
Figure 3: Association between CD5 and NF-κB/STAT3 activation in DLBCL and the independent prognostic 
significance of CD5 expression . (A-D) Association of CD5 expression with nuclear expression of c-Rel and p65; (E) CD5 expression 
was associated with decreased nuclear expression of p50 in ABC-DLBCL; (F-G) Comparison of nuclear expression of p52 and RelB 
between CD5+ and CD5– patients; (H) CD5 expression was associated with STAT3 activation in ABC-DLBCL; (I-P) The prognostic 
significance of CD5+ was independent of c-Rel, p65 or STAT3 activation. 
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36]. Furthermore, the prognostic significance of CD5 
expression was restricted to DLBCLs without or with 
very low SSBP2 expression. In SSBP2+ patients, CD5 
expression in DLBCL was not associated with prognosis 
(Figures 4E-H).
In ABC-DLBCL, Bcl-2+ vs. Bcl-2– also had 
decreased SSBP2 mRNA and protein expression 
independent of CD5 expression (Figures 4I-J, 
Supplemental Figures 1P-Q). However, the prognostic 
significance of Bcl-2 was independent of SSBP2 
expression (Figures 4K-L).
Multivariate survival analysis 
Multivariate analysis of clinical and pathological 
factors including IPI (defined by age, stage, serum 
LDH, performance status, and extranodal sites), sex, 
B-symptoms and tumor size, CD5+, Bcl-2+, and COO 
confirmed that CD5 expression independently predicted 
significantly poorer OS (P = .005) and PFS (P = .014) in 
DLBCL, in addition to the known unfavorable prognostic 
factors IPI >2 and Bcl-2+ (Table 3). COO classification 
did not reach statistical significance to be an independent 
factor in this multivariate analysis, but did remain as an 
independent prognostic factor after removal of CD5 as 
a factor in the survival analysis, suggesting that CD5 
expression significantly contributed to the poor prognosis 
of ABC-DLBCL.
The prognostic significance of these variables 
(except COO) was further analyzed in the ABC-DLBCL 
subset. CD5 positivity remained as an independent 
prognostic factor predicting poorer OS (P = .032). 
However, the P value for PFS did not reach statistical 
significance (P = .12). IPI>2 and Bcl-2+ remained 
independent prognostic factors for both OS and PFS 
(Table 3).
Prognostic and biological impact of cd5 
expression in the validation set 
In an independent validation set from multiple 
medical centers, we validated the prognostic significance 
(Figures 5A-B) as well biological impact of CD5+ 
discovered in the training set. In the validation set, CD5+ 
DLBCL were also associated with elevated Bcl-2 and 
decreased SSBP2 expression (Figures 5C-D), and its 
prognosis was independent of Bcl-2+ (Figures 5E-F) but 
depended on SSBP2– (Figures 5G-H). 
In both the training and validation sets, the 
Figure 4: correlation between cd5 and ssbP2 expression in dlbcl. (A-D) CD5 expression was correlated with decreased 
SSBP2 expression; (E-F) The prognostic significance of CD5+ was present only in patients without  SSBP2 expression; (G-H) CD5+ was 
not prognostic in patients with SSBP2 expression; (I-J) Bcl-2+ compared with Bcl-2– patients had decreased SSBP2 mRNA and protein 
levels only in the ABC-DLBCL subset but not in the GCB-DLBCL subset; (K-L) The prognostic significance of Bcl-2+ was independent 
of SSBP2 expression.
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Figure 5: biological and prognostic impact of cd5 expression in the validation dlbcl cohort. (A-B) CD5 expression 
was correlated with significantly poorer OS and PFS in the overall DLBCL cohort; (C-D) CD5 expression was correlated with Bcl-2 
overexpression and decreased SSBP2 expression; (E-F) The prognostic significance of CD5+ was independent of Bcl-2 overexpression; 
(G-H) The prognostic significance of CD5+ in the validation DLBCL cohort depended on loss of SSBP2 expression; (I-L) The prognostic 
significance of CD5+ was independent of the IPI.
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prognostic significance of CD5+ was independent of the 
IPI. Figures 5I-L shows analysis in the combined training 
and validation sets. 
Effect of CD5 expression on BCR/TCR signaling 
CD5+ DLBCL had significantly higher levels of 
CARD11/CARM1 mRNA compared with CD5– DLBCL 
(Figure 6A). CARD11 is a scaffold protein downstream 
of BCR signaling that activates NF-κB via interaction 
with BCL10 [32,37,38]. A20, a negative regulator of NF-
κB signaling [37], and IL10, which mediates immune 
inhibition and cell survival downstream the CD5 signaling 
[10,11], did not show differential expression of mRNAs 
between CD5+ and CD5– DLBCL patients. (P= .30 and 
P= .36). In addition, TCL1A (which modulates AKT 
activation downstream of the TCR signaling [39]) and 
BCL11A (proto-oncogene with a critical role in lymphoid 
development [40]), which was often co-amplified with 
REL in lymphoid malignancies [41,42], were significantly 
upregulated in CD5+ ABC-DLBC patients (Figures 6B-
C). PTEN encoding a tumor suppressor antagonizing the 
PI3K/AKT signaling was significantly downregulated in 
CD5+ GCB-DLBCL (Figure 6D).
Differential expression of CARD11, TCL1A, and 
BCL11A between Bcl-2+ and Bcl-2– DLBCL patients 
resembled the effect of CD5 signaling (Figures 6E-G), 
suggesting that there are similar signaling pathways 
potentially underlying the association of CD5 and Bcl-2 
expression. In contrast, regulation of other genes such as 
A20 (Figure 6H), PTEN, CD10, PIK3CA, MYC, CXCL12, 
PRDM1, STAT3 showed different patterns in Bcl-2+ (vs. 
Bcl-2–) and CD5+ (vs. CD5–) patients. 
cd5 expression signatures in de novo dlbcl
Gene expression profiles of CD5+ and CD5– DLBCL 
were compared to identify CD5 gene signatures in de 
novo DLBCL, which showed 86 differentially expressed 
genes (DEGs) by comparison within the overall cohort, 
and 39 DEGs by comparison within the ABC-DLBCL 
subcohort (Figures 5A-B, Table 4). Comparison within 
the GCB-DLBCL subcohort with limited CD5+ cases 
found 17 DEGs, most of which are related to cytoskeleton, 
microtubule or nervous system function (Figure 5C). Only 
a few genes were found expressed differentially between 
CD5+ GCB- and ABC-DLBCLs (Table 5). 
CD5 expression signatures included both activators 
and inhibitors of TCR/BCR signaling. Activation of 
BCR/TCR was suggested by upregulation of CARD11, 
CLECL1 (encoding a T-cell costimulatory molecule), 
and IGHM. However, inhibition of BCR/TCR and 
increased threshold for activation in CD5+ DLBCL was 
also suggested by upregulation of PTPN2 and SIT1 
(which negatively regulate TCR signaling), LYN (which 
has roles in inhibiting BCR), and SH3BP5 (which 
inhibits BTK signaling), and downregulation of PDE4D 
(which hydrolyzes c-AMP, thereby removing the c-AMP 
constraint for TCR) in CD5+ DLBCL [43].
DEGs downstream of TCR/BCR also suggested 
activated BCR signaling with negative feedback in 
CD5+ DLBCL. Activation of the NF-κB, MAPK, 
and Wnt pathways was indicated by upregulation of 
CXXC5 (activating NF-κB and MAPK) and GLYR1 
Figure 6: mrnA expression of bcr signaling-related genes between cd5+ and cd5– dlbcl patients, or bcl-2+ and 
bcl-2– dlbcl patients. (A-B) Association of CD5 expression with upregulated CARD11 and TCL1 mRNA levels; (C) CD5 expression 
was associated with increased BCL11A mRNA in ABC-DLBCL; (D) CD5 expression was associated with decreased PTEN mRNA in GCB-
DLBCL; (E-H) Differential expression of CARD11, TCL1, BCL11A and A20 between Bcl-2+ and Bcl-2– patients resembled the patterns 
between CD5+ and CD5– DLBCL patients.
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(activating MAPK) and downregulation of APCDD1 
(negative regulator of Wnt signaling), PI15 (trypsin 
inhibitor), CAMK2N1 (CAMK2 inhibitor), PPM1L 
(dephosphorylating MAPKs), and PTPRR (sequester 
and inhibitor of MAPKs). In turn, antiapoptotic BCL2 
and TNFAIP8 downstream of the NF-κB pathway were 
significantly upregulated. On the other hand, inhibition 
of the calcium-dependent signaling, which is required for 
the activation of proteins downstream BCR including NF-
κB and NFAT [44,45], was indicated by upregulation of 
BSPRY (inhibiting calcium influx) and downregulation of 
SGK1, which activates ion channels and calcium entry. 
CD5 expression signatures also included 18 
transcription factors, suggesting distinct transcription 
programs in CD5+ DLBCL patients. Upregulated 
transcription factors included CREB3L2 (a transcription 
activator binding to the cAMP response element), 
ETV6 (a transcriptional repressor), FOXP1 (an essential 
transcriptional repressor of B-cell development), 
IRF2BP2 (a transcription corepressor repressing the 
NFAT target genes including IL2/IL4), JARID2 (a 
transcriptional repressor), TCF4 (a transcription factor 
binding to the immunoglobulin enhancer), and ZNF589 
(a transcriptional repressor). Downregulated transcription 
factors included LIM factors LMO2, LMO4, and LHX2 
(which have roles in proliferation, differentiation and 
hematopoietic development), MAML3 (a transcriptional 
coactivator for NOTCH proteins), TFEC (which binds to 
the immunoglobulin heavy-chain/IGH gene enhancer), 
and MYBL1 (a strong transcriptional activator). Altogether 
it appears that transcription factors that repress TCR/
BCR signaling and proliferation outnumbered those that 
enhance TCR/BCR signaling. 
Cell cycle and proliferation genes also appeared 
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under concurrent positive and negative regulations in CD5+ 
DLBCL. Three genes promoting cell cycle progression 
were upregulated, including CCND2 (a cyclin important 
for G1/S transition), CDK3 (a cyclin-dependent protein 
kinase involved in G0-G1 and G1-S transitions), and 
TLK1 (a kinase involved in the regulation of chromatin 
assembly), whereas NEK6 (playing an important role 
in mitotic cell cycle progression) was downregulated. 
JARID2 (which negatively regulates cell proliferation 
signaling) was upregulated, and CLEC11A, PTK2, 
MYBL1, and SGK2 genes (which stimulate proliferation) 
were downregulated.
Supporting a previous study [25], another 
distinctive feature of the CD5 expression signatures were 
the downregulation of genes related to cell adhesion, 
ECM remodeling, and migration (CCBE1, COL5A1, 
COL6A3, ENPP3, FAM198B, FN1, ITGBL1, PCDH9, 
PTK2, RAPH1, and MYO7A). LTBP1 (functioning in the 
assembly, secretion, and targeting of TGFβ1 to ECM), 
INHBA (encoding a TGFβ family member), and PTPRB 
(involved in blood vessel remodeling and angiogenesis) 
were downregulated in CD5+ DLBCL. 
Gene set enrichment analysis (GSEA) was 
performed to enrich the relevant pathways. Downregulated 
“ECM Receptor Interaction and upregulated “Nitrogen 
Metabolism” had nominal P-values < 1% ( .006 and .0039 
respectively) although no gene sets were enriched by an 
FDR threshold of 25% (probably due to the small number 
of CD5+ cases, and the highly heterogeneous nature of 
CD5– DLBCL patients). In addition, “Focal Adhesion” had 
a nominal P-value of .026 with an FDR of 30%. These 
results reinforced the notion that downregulation of genes 
involved in ECM and cell adhesion is a prominent feature 
of the CD5 expression signature (Figures 5D-F). Pathway 
analysis by the Ingenuity Pathway Analysis (IPA) software 
showed CD5 expression signatures were associated 
with functional networks of Hematopoiesis, Nervous 
System Development and Function, Cellular Growth and 
Proliferation (Supplemental Figure 2). 
dIscussIon
De novo CD5+ DLBCL is a unique subset of DLBCL 
[1] and has not been studied on a large scale in Western 
countries. The current study of 879 patients with de novo 
DLBCL identified 48 (5.5%) CD5+ patients, associated 
with higher frequencies of >1 ECOG performance status, 
BM involvement, CNS relapse, ABC subtype, Bcl-2+, 
and STAT3 activation whereas with lower frequencies 
of CD30+, SSBP2+, and MYC mutations. CD5 signaling 
appears to differentially regulate NF-κB subunits, 
activating c-Rel and p65 but decreasing p50 activation. 
Other features associated with CD5+ DLBCL in this 
study, such as elderly age, B-symptoms, IPI, GCET, 
CD10, FOXP1 and CXCR4, were probably due to the 
predominance of ABC subtype of CD5+ DLBCL patients. 
Compared with previous studies conducted in Japan, 
CD5+ DLBCL in Western countries had lower prevalence, 
shared common features of performance status, ABC 
subtype, Bcl-2 overexpression, BM involvement, and 
development of CNS recurrence, but lacked features of 
female predominance, extranodal involvement, elevated 
serum LDH, and higher disease stage [13-15,17-19]. 
These differences may reflect ethnic and genetic variation, 
the heterogeneity of CD5+ DLBCL, the larger number 
of CD5+ DLBCLs (n = 109) in the Japanese cohort and 
cohort-specific features.
We further assessed the prognostic impact of CD5 
Figure 7: Gene expression profiling and gene set enrichment analysis of CD5+ dlbcl. (A-C) Gene expression profiling of 
CD5+ vs. CD5– patients in the overall, ABC-, and GCB -DLBCL cohorts; (D-F) Gene set enrichment analysis of CD5 expression signatures.
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expression and found that CD5+ independently correlated 
with poorer survival in DLBCL with R-CHOP treatment. 
Moreover, the 48 CD5+ DLBCL patients treated by 
R-CHOP in this study cohort did not show significant 
improvement in OS (P= .66) or PFS (P= .81) compared 
to the 14 CD5+ DLBCL patients treated with CHOP from 
an independent CHOP-treated DLBCL cohort (results 
not shown). Furthermore, our attempt to understand 
the biology of CD5+ DLBCL suggested that molecular 
pathways downstream BCR signaling which promote cell 
proliferation and survival (such as Bcl-2 [but not Myc] 
overexpression, and activation of c-Rel, p65, and STAT3) 
were likely relevant for the pathogenesis of CD5+ DLBCL; 
however, the adverse impact of CD5 expression did not 
depend on any of these factors alone. 
BM involvement also appeared to impact prognosis 
of CD5+ DLBCL significantly in the training set (Figures 
1J-K, which however was not confirmed in the validation 
set), and development of CNS relapse (0% at diagnosis, 
8.3% after treatment) was remarkable for CD5+ DLBCL. 
A role of CXCR4/CXCL12 axis in BM involvement and 
CNS relapse of CD5+ DLBCL was suggested by the higher 
CXCR4 expression in the studied CD5+ DLBCL patients 
(Supplemental Figure 1E) [28,46]. However, restricting 
within ABC-DLBCL, CD5+ compared to CD5– patients 
had similar levels of CXCR4 but had a higher incidence 
of BM involvement (34.5% vs. 7.2%, P < .0001, Table 2), 
suggesting that CXCR4/CXCL12 axis was not sufficient to 
explain for the BM involvement. A previous study in CLL/
SLL also suggested that other factors in addition to the 
CXCR4/CXCL12 axis may account for marrow infiltration 
of neoplastic cells [46]. In this study, downregulation of 
genes involved in ECM and cell adhesion, which was a 
prominent feature of the CD5+ signature revealed by GEP 
analysis, likely contributed to the BM involvement and 
development of CNS relapse in CD5+ DLBCL.
Interestingly, CD30 and SSBP2 (a tumor-suppressor 
[34,36,47]) expression was frequently negative in CD5+ 
DLBCL patients. SSBP2 has a critical regulatory role in 
the transcriptional program of hematopoietic stem and 
progenitor cells in vivo, via modulating the abundance 
and function of multiple transcription cofactors including 
LIM domain-binding protein 1 (LDB1), LMO, and LHX. 
In mouse models, loss of SSBP2 resulted in hypoplastic 
hematopoietic tissues and impaired hematopoiesis and 
was associated with shortened lifespan and greater 
susceptibility to B-cell lymphomas [34,35,48]. Prognostic 
significance of CD5 expression in SSBP2+ and SSBP2– 
DLBCL patients also suggests a tumor-suppressor function 
of SSBP2 for CD5 signaling. 
GEP analysis suggested both positive and negative 
regulation of TCR/BCR in CD5+ DLBCL patients, and 
differential regulation of BCR downstream pathways 
(activation of NF-κB, MAPK, and Wnt pathways and 
inhibition of calcium influx). This may suggest the 
activated but reprogrammed BCR signaling in CD5+ 
DLBCL patients, and the role of CD5 expression in 
mitigating BCR signaling, and promoting tumor cell 
survival by previous studies [7-10]. Likewise, both 
positive and negative regulations of proliferation, 
growth, and cell cycle were suggested by CD5 expression 
signatures. Therefore it appears that CD5 signaling 
contributes to survival yet an anergic-like state of B-cells. 
It is also possible that the unique characteristics 
of the CD5 expression signature in antiapoptosis, 
proliferation, signaling, and transcription reflects the 
COO and the differentiation stages of the lymphoma 
cells. For example, downregulated LMO2, LMO4, LHX2, 
and CLEC11A as well as upregulated FOXP1, ZNF589, 
LYN, and BCL2 are hematopoietic mediators and have 
distinct expression patterns during B-cell development. 
In addition, IGHM expressed in naïve B-cells and 
plasma cells was upregulated in CD5+ patients, whereas 
MYC mutations, which may arise from an aberrant 
hypermutation process in DLBCL [49], were almost absent 
in CD5+ DLBCL patients (only one CD5+ GCB-DLBCL 
case had MYC mutations). Previous studies indicated that 
CD5+ DLBCL and CD5+ CLL had higher frequencies 
of germline vs. somatically hypermutated IGHV genes 
compared with CD5– DLBCL [50], suggesting the COO of 
CD5+ DLBCL might be distinct from that of CD5– DLBCL 
and yet similar to that of CD5+ CLL [51]. Our collective 
results of GEP, MYC mutations, and Blimp-1 expression 
(indicating commitment to plasma cell differentiation) 
[52-54] in CD5+ and CD5– DLBCL (Tables 2, 4) suggest 
that subsets of CD5+ DLBCL may originate from pre-GC, 
memory B-cells, or neoplasms differentiated into plasma 
cells yet never through GC reaction [60, 61]. 
In summary, in this study we show that de novo 
CD5+ DLBCL, which occurs at a low frequency (5.5%) 
in Western countries, was associated with unfavorable 
clinicopathologic variables and with inferior survival 
following R-CHOP treatment. Although heterogeneity still 
exists in this disease subset, dysregulated BCR signaling 
is significantly implicated in lymphoma cell survival and 
disease dissemination. Bcl-2 inhibitors, STAT3 inhibitors, 
and therapeutic strategies modulating BCR signaling, 
tumor microenvironment and cytokine/chemokine axes 
may help in the management of CD5+ DLBCL patients.
MAterIAls And Methods
Patients
This study was part of the International DLBCL 
Rituximab-CHOP Consortium Program, comprising a 
total of 879 patients (538 patients in the training set and 
341 patients in the validation set) with de novo DLBCL 
who were treated with R-CHOP chemotherapy. Patients 
who had a history of low-grade B-cell lymphoma, 
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primary mediastinal, cutaneous, or central nervous system 
DLBCL, or human immunodeficiency virus infection 
were excluded. All patients were reviewed by a group 
of hematopathologists and were diagnosed according to 
the World Health Organization classification criteria. The 
study was conducted in accordance with the Declaration 
of Helsinki, and the protocol was reviewed and approved 
by the Institutional Review Boards of each participating 
center, and the comprehensive collaborative study was 
approved by the Institutional Review Board at The 
University of Texas MD Anderson Cancer Center. 
tissue microarray and biomarkers
Immunohistochemical analysis for CD5 expression 
using a monoclonal CD5 antibody (Novocastra Labs, UK) 
was performed on 879 DLBCL biopsy specimens using 
formalin-fixed, paraffin-embedded tissue microarrays as 
described previously [55,56]. CD5 expression was scored 
by three pathologists independently on 400 cells in each of 
cases under a microscope at 40× magnification. Expression 
of other markers such as CD10, GCET1, MUM1, FOXP1, 
Bcl-6, Bcl-2, Myc, Ki-67, p53, MDM2, NF-κB subunits, 
pSTAT3, CD30, CXCR4, and SSBP2 [31,33,55-59] was 
also assessed using respective antibodies. SSBP2 antibody 
was kindly provided by Dr. Lalitha Nagarajan, PhD from 
the Department of Genetics, MD Anderson Cancer Center 
[34,36]. Due to tissue exhaustion, IHC analysis for some 
markers other than CD5 was not successful in few cases. 
Gene translocations and amplifications were detected 
using the methods described previously [30,31,59]. MYC 
mutation was detected using the Sanger sequencing 
method. 
Cell-of-origin classification
Cell-of-origin classification as either GCB or ABC 
DLBCLs was determined by GEP for patients in the 
training set and by IHC according to the Visco-Young 
algorithm and/or Choi algorithms [55] for all the patients 
in the training and validation sets. 
Gene expression profiling
GEP were achieved in 488 DLBCL (27 CD5+ and 
461 CD5–) patients of the training set using total RNAs 
extracted from each formalin-fixed, paraffin-embedded 
tissue sample and Affymetrix GeneChips array as 
described previously [30,55,57,58]. The microarray data 
were quantified and normalized, and the DEGs between 
CD5+ and CD5– DLBCL patients at false discovery rate 
of .01 were identified using multiple t-tests. Gene set 
enrichment analysis was performed on the KEGG pathway 
gene sets. Pathway analysis for the DEGs was performed 
using the Ingenuity Pathway Analysis software program 
(IPA, http://www.qiagen.com/ingenuity). 
statistical analysis
Clinicopathologic differences between different 
DLBCL subgroups were assessed using Fisher’s exact 
test and the Spearman rank correlation. The mRNA 
expression levels of affected genes were also retrieved 
from the GEP data and compared between CD5+ and 
CD5– DLBCL patients using unpaired t tests. Overall 
survival was calculated from the time of diagnosis to 
death from any cause or last follow-up. Progression-
free survival was calculated from the time of diagnosis 
to disease progression, relapse, or death from any 
cause. Patients who were alive and/or had no disease 
progression were censored at last follow-up. Survival 
analysis was performed using the Kaplan–Meier method 
with GraphPad Prism 6 (GraphPad Software, San Diego, 
CA), and differences were compared using the log-rank 
test. Multivariate survival analysis was performed using 
the Cox proportional hazards regression model with the 
SPSS statistics software program (version 19.0; IBM 
Corporation, Armonk, NY). All differences with P ≤ .05 
were considered statistically significant.
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